Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

Future oncology (London, England) - 1 Feb 2017

Avrillon Virginie, Pérol Maurice

Abstract excerpt

Alectinib is a highly selective second-generation ALK inhibitor that is active against most crizotinib ALK resistance mutations, with a good penetration in CNS and a good safety profile. Thanks to the positive results of Phase II trials, alectinib was approved in Japan and by the US FDA for ALK-positive non-small-cell lung cancer (NSCLC) patients pretreated with crizotinib. Recently, the Phase III J-ALEX study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Evaluation, Preclinical
Share to Anaplastic Lymphoma Kinase
Share to Carbazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Discovery

Share to Drug Resistance, Neoplasm

Share to Piperidines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 27780368
DOI: 10.2217/fon-2016-0386

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alectinib for treatment of ALK-positive non-small-cell lung cancer.PMID 27780368Read ↗

Alectinib for advanced ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity Read ↗

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.Semantic proximity Read ↗

Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.Semantic proximity Read ↗

[Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: A Case Report and Literature Review].Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?Semantic proximity Read ↗

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to dateSemantic proximity Read ↗

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma CellsSemantic proximity Read ↗

Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.